AbbVie Inc. (NYSE:ABBV) is among the high growth mega cap stocks you can buy and hold for the next 3 years. Evan Seigerman, an analyst at BMO Capital, increased the price target on AbbVie Inc. (NYSE:ABBV) to $240 from $215 with an ‘Outperform’ rating. This potential upside of nearly 10% follows the company’s announcement that it has resolved litigation with generic drugmakers, allowing for the early market entry of generic Rinvoq. Many believe that generic competition market entry won’t occur until 2037, ...

Key Takeaways AbbVie stock is up 22.5% in 2025, beating its industry, sector and the S&P 500 index.Strong sales of Skyrizi and Rinvoq are replacing Humira and driving top-line growth.Acquisitions in immunology, oncology and neuroscience strengthen AbbVie's pipeline.AbbVie (ABBV) has gained 22.5% so far this year against a decrease of 0.1% for the industry. The stock has also outperformed the sector and the S&P 500 index, as seen in the chart below.ABBV Stock Outperforms Industry, Sector & S&P 500Image Sourc ...

AbbVie Inc. (NYSE:ABBV) is included among the 13 Best Consistent Dividend Stocks to Buy Now. AbbVie (ABBV)'s Dividend Track Record: How It Became a Leader in Consistent Dividends AbbVie Inc. (NYSE:ABBV) is an Illinois-based pharmaceutical company. It has delivered strong results in 2025, easily beating the broader market. Much of this momentum comes from solid growth in sales and adjusted earnings, driven largely by its autoimmune treatments Rinvoq and Skyrizi. The stock has surged by nearly 22% since th ...

Overall, Wall Street rates NEE stock as a “Moderate Buy.” Of the 21 analysts that cover the stock, 12 rate it a “Strong Buy,” eight suggest a “Hold,” and one suggests a “Strong Sell.” Based on the average target price of $82.17, the stock has an upside potential of 15.6% from current levels. Its Street-high estimate of $97 further implies NEE stock can go as high as 36.5% in the next 12 months.It pays a dividend yield of 3.1%, compared to the utilities sector average of 3.7%. NextEra has a strong track reco ...

In this article, we will take a look at some of the best dividend stocks with consistent payouts.Investors have been rushing into high-dividend stocks, attracted by the promise of strong payouts as interest-rate cuts are anticipated later this year.According to Purpose Investments Inc., the five largest dividend-focused exchange-traded funds saw inflows of $17.5 billion by mid-July, almost ten times higher than at the beginning of 2024. However, the challenge for income seekers is that fewer US companies ar ...

Dividends are powerful portfolio boosters, and AbbVie is a dividend dynamo.AbbVie (ABBV -0.32%) is a drug company, spun off from Abbott Laboratories in 2013, that you might want to consider for your long-term portfolio. One of the biggest green flags for investing in the company is its dividend. AbbVie's recent dividend yield was a solid 3.1% -- the S&P 500's recent yield was a mere 1.2% -- and better still, it has been growing, with plenty of room to keep doing so.Over the past five years, AbbVie hiked its ...

Key Takeaways AbbVie settled with generic drugmakers, extending Rinvoq exclusivity until April 2037.Rinvoq sales jumped 48% to $3.75B, now 13% of AbbVie's total revenue.New indications may add $2B to Rinvoq's peak sales, reinforcing AbbVie's growth outlook.Shares of AbbVie (ABBV) rose over 4% to a record high on Thursday after the company announced that it had settled patent litigation with all generic manufacturers who had sought the FDA’s approval for generic versions of its blockbuster immunology drug, R ...

The company is dealing with declining sales of its former cash-cow drug Humira. ...

核心事件 - 艾伯维与仿制药企达成和解协议 将Rinvoq专利保护期从2033年延长至2037年4月 [1][2] - 该协议为Rinvoq franchise提供长期保护 超出华尔街预期 [3] 市场反应 - 股价突破杯柄形态基底买入点212.45美元 早盘大涨4.3%至220.74美元 [3] - IBD相对强度评级获上调 显示价格表现改善 [10] 财务影响 - Rinvoq 2024年销售额达59.7亿美元 占总销售额近11% [5] - Skyrizi同期销售额117.2亿美元 占比约21% [5] - 管理层此前指引2027年Rinvoq和Skyrizi销售额分别超110亿和200亿美元 [7] 产品管线进展 - 针对斑秃患者的两项研究取得积极结果 计划向FDA提交新适应症申请 [6] - 正在开发白癜风、化脓性汗腺炎和系统性红斑狼疮等新适应症 [6] - 新适应症获批预计可为峰值销售额增加约20亿美元 [7] 历史对照 - 类似协议曾用于明星药Humira 其生物类似药2023年上市后销售额迅速下滑 [4] - Rinvoq和Skyrizi已成功接棒Humira 收入显著增长 [5]

核心事件 - 公司与仿制药制造商达成重大协议 将Rinvoq的仿制药上市时间推迟至2037年[2] - Rinvoq去年销售额达60亿美元 同比增长50% 今年上半年销售额已达37亿美元[2] - 该协议使Rinvoq有望实现超过120亿美元的峰值销售额[2] 财务表现 - 近12个月营收从550亿美元增长至580亿美元 增幅6.1%[6] - 最近季度营收从140亿美元增长至150亿美元 增幅6.6%[6] - 过去三年营收平均增长率为0.6%[6] - 过去四个季度营业利润为140亿美元 营业利润率23.5%[13] - 营业现金流为190亿美元 现金流利润率33.1%[13] - 净利润为38亿美元 净利润率6.5%[13] 估值水平 - 市销率6.8倍 高于标普500的3.2倍[6] - 市盈率104.8倍 显著高于标普500的24.1倍[6] - 市现率21.6倍 与标普500的21.2倍基本持平[6] - 当前交易价格约为每股210美元 今年累计上涨18%[2][14] 资产负债 - 总资产1370亿美元 其中现金及等价物65亿美元[13] - 现金资产占比4.7% 低于标普500的7.0%[13] - 债务总额700亿美元 市值3740亿美元[13] - 资产负债率17.9% 优于标普500的20.9%[13] 市场表现 - 在2022年通胀冲击中下跌23.3% 优于标普500的25.4%跌幅[14] - 在2020年疫情危机中下跌34.0% 与标普500的33.9%跌幅基本持平[14] - 两次危机后均实现完全复苏并创出新高[14]